David Westerman

6.5k total citations · 2 hit papers
125 papers, 2.8k citations indexed

About

David Westerman is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, David Westerman has authored 125 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Genetics, 45 papers in Pathology and Forensic Medicine and 42 papers in Hematology. Recurrent topics in David Westerman's work include Chronic Lymphocytic Leukemia Research (59 papers), Lymphoma Diagnosis and Treatment (44 papers) and Acute Myeloid Leukemia Research (21 papers). David Westerman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (59 papers), Lymphoma Diagnosis and Treatment (44 papers) and Acute Myeloid Leukemia Research (21 papers). David Westerman collaborates with scholars based in Australia, Germany and United States. David Westerman's co-authors include John F. Seymour, Constantine S. Tam, H. Miles Prince, Andrew W. Roberts, Mary Ann Anderson, Piers Blombery, Stephen Lade, David C.S. Huang, Dennis Carney and David Ritchie and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

David Westerman

120 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

2018 276 citations Piers Blombery, Mary Ann Anderson et al. Cancer Discovery profile →
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

2018 274 citations Constantine S. Tam, Mary Ann Anderson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Westerman Australia	27	1.4k	1.4k	776	732	576	125	2.8k
Aspasia Stamatoullas France	34	1.2k 0.8×	1.7k 1.3×	1.3k 1.7×	1.4k 1.9×	415 0.7×	126	3.6k
Nishitha Reddy United States	21	1.0k 0.7×	1.4k 1.0×	1.0k 1.3×	511 0.7×	378 0.7×	116	2.3k
Achille Ambrosetti Italy	24	1.3k 0.9×	1.5k 1.1×	713 0.9×	798 1.1×	383 0.7×	67	2.8k
Simon Rule United Kingdom	30	1.6k 1.1×	2.4k 1.7×	1.7k 2.2×	593 0.8×	320 0.6×	155	3.4k
Stephen Opat Australia	25	1.4k 1.0×	1.7k 1.2×	980 1.3×	570 0.8×	446 0.8×	158	2.7k
Françoise Rigal‐Huguet France	25	837 0.6×	1.0k 0.7×	869 1.1×	1.3k 1.7×	692 1.2×	66	2.7k
Sergio Cortelazzo Italy	31	1.9k 1.3×	2.1k 1.5×	1.3k 1.6×	1.5k 2.1×	739 1.3×	117	4.5k
B Desablens France	23	1.2k 0.9×	1.4k 1.0×	744 1.0×	854 1.2×	346 0.6×	89	2.6k
Marı́a Dolores Caballero Spain	32	586 0.4×	1.4k 1.0×	1.2k 1.5×	1.1k 1.5×	407 0.7×	74	2.8k
Meyer R. Heyman United States	14	924 0.6×	1.4k 1.0×	1.1k 1.5×	436 0.6×	396 0.7×	22	2.8k

Countries citing papers authored by David Westerman

Since Specialization

Citations

This map shows the geographic impact of David Westerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Westerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Westerman more than expected).

Fields of papers citing papers by David Westerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Westerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Westerman. The network helps show where David Westerman may publish in the future.

Co-authorship network of co-authors of David Westerman

This figure shows the co-authorship network connecting the top 25 collaborators of David Westerman. A scholar is included among the top collaborators of David Westerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Westerman. David Westerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Handunnetti, Sasanka M., Amit Khot, Piers Blombery, et al.. (2025). Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma. Blood Advances. 10(5). 1733–1742.

Handunnetti, Sasanka M., Mary Ann Anderson, Kate Burbury, et al.. (2024). Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 144(8). 867–872. 7 indexed citations

Nguyen, Phillip, Tamia Nguyen, Ing Soo Tiong, et al.. (2023). Evaluation of T‐cell clonality by anti‐TRBC1 antibody‐based flow cytometry and correlation with T‐cell receptor sequencing. British Journal of Haematology. 204(3). 910–920. 2 indexed citations

Thompson, Ella R., Tamia Nguyen, John Markham, et al.. (2021). Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors. Blood Advances. 6(2). 503–508. 17 indexed citations

Lew, Thomas E., Mary Ann Anderson, Victor S. Lin, et al.. (2020). Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Advances. 4(1). 165–173. 31 indexed citations

Goncalves, Isaac, Kate Burbury, David Westerman, et al.. (2019). Characteristics and Outcomes of Therapy-Related Myeloid Neoplasms after Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Neoplasm (NEN): A Single Centre Series. Neuroendocrinology. 108. 2 indexed citations

Blombery, Piers, Mary Ann Anderson, Jianan Gong, et al.. (2018). Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery. 9(3). 342–353. 276 indexed citations breakdown →

Anderson, Mary Ann, Jing Deng, John F. Seymour, et al.. (2016). The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 127(25). 3215–3224. 215 indexed citations

Tam, Constantine S., Andrew W. Roberts, Mary Ann Anderson, et al.. (2016). The combination of ibrutinib and venetoclax (ABT-199) rapidly achieves complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study. Haematologica. 3 indexed citations

10.

Herbert, Kirsten, Glen Wiesner, Emma Link, et al.. (2014). Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. Bone Marrow Transplantation. 49(8). 1056–1062. 12 indexed citations

11.

Spruyt, Odette, David Westerman, Alvin Milner, Mathias Bressel, & Simon Wein. (2013). A randomised, double-blind, placebo-controlled study to assess the safety and efficacy of methoxyflurane for procedural pain of a bone marrow biopsy. BMJ Supportive & Palliative Care. 4(4). 342–348. 25 indexed citations

12.

Cheah, Chan Y., Michael S. Hofman, Michael Dickinson, et al.. (2013). Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. British Journal of Cancer. 109(2). 312–317. 50 indexed citations

13.

Blombery, Piers, et al.. (2011). Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. Annals of Hematology. 90(10). 1167–1172. 26 indexed citations

14.

Blombery, Piers, Stephen Q. Wong, Chelsee Hewitt, et al.. (2011). Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica. 97(5). 780–783. 52 indexed citations

15.

Carney, Dennis, David Westerman, Constantine S. Tam, et al.. (2010). Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 24(12). 2056–2062. 68 indexed citations

16.

Peinert, Stefan, Constantine S. Tam, M Wolf, et al.. (2009). FLUDARABINE BASED COMBINATION THERAPY IS HIGHLY ACTIVE AS PRIMARY OR SALVAGE TREATMENT IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA. 94. 1 indexed citations

17.

Peinert, Stefan, Margaret F. Moloney, H. Miles Prince, et al.. (2009). RAPID INFUSION OF RITUXIMAB IS WELL TOLERATED AND ENABLES MORE EFFICIENT USE OF HAEMATOLOGY DAY WARD RESOURCES. 94. 2 indexed citations

18.

Tam, Constantine S., Max Wolf, E. Januszewicz, et al.. (2004). A new model for predicting infectious complications during fludarabine‐based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer. 101(9). 2042–2049. 22 indexed citations

19.

Prince, H. Miles, Dominic Wall, Danny Rischin, et al.. (2002). CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy. 4(2). 147–155. 7 indexed citations

20.

Juneja, Surender, et al.. (2000). Paraffin Section Immunotyping of Leukaemias. British Journal of Haematology. 109(2). 267–271. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact